Aenova Group DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

New Managing Director at Aenova's Regensburg site

21 Mar 2025

// PRESS RELEASE

Aenova recognized as a winner of CDMO Leadership Awards 2025

07 Mar 2025

// PRESS RELEASE

Aenova invests in packaging & production at its Bad Aibling site

04 Mar 2025

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

BioProcess International Europe

Attending

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

22 Corporate Content #SupplierSpotlight, 3 Data Compilation #PharmaFlow, 57 News #PharmaBuzz

media
22 Corporate Content #SupplierSpotlight
3 Data Compilation #PharmaFlow
57 News #PharmaBuzz

SERVICES

Packaging, Drug Product Manufacturing, API & Drug Product Development

pharmaServices
Packaging
- 1 Contract Services
Drug Product Manufacturing
API & Drug Product Development
- 10 Formulation Development

KEY SERVICES

Contract Manufacturing for Tablets, Controlled Substance Oral Solids, Hard Capsule Contract Manufacturing, Vegetarian Hard Capsules, Effervescent Tablet Manufacturing, Immediate & Modified Release Tablets, HPAPI High Potent Oral Solids, Micro-dosed Capsules, Controlled Substance Oral Solid Dose, Lozenges & Chewable Tablets Development, CDMO for Chewable gels / Gummies, CDMO for Orally Dispersible Tablets /ODT, Immediate & Modified Release Capsules, Non-Sterile Liquids

Contract Manufacturing for Tablets
Controlled Substance Oral Solids
Hard Capsule Contract Manufacturing
Vegetarian Hard Capsules
Effervescent Tablet Manufacturing
Immediate & Modified Release Tablets
HPAPI High Potent Oral Solids
Micro-dosed Capsules
Controlled Substance Oral Solid Dose
Lozenges & Chewable Tablets Development
CDMO for Chewable gels / Gummies
CDMO for Orally Dispersible Tablets /ODT
Immediate & Modified Release Capsules
Non-Sterile Liquids

INSPECTIONS & REGISTRATIONS

48 FDA, 8 EDQM, 7 GDUFA

inspections
48 FDA
8 EDQM
7 GDUFA

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

About

Aenova is a leading CDMO in the global pharmaceutical industry. With operations in Europe and the US, services span from early phase development to commercial manufacturing for all common dosage forms from solids to sterile injectables. Specialty technologies include HPAPI, micro-dosing, modified release, organic granulation, particulate systems, lipid-based systems, hot melt extrusion or spray drying for poorly soluble compounds. Excellence and Reliability are core Aenova values, reflected through ample capacities, backup sourcing within the group, and ongoing capital investments, resulting in strong and enduring client partnerships.

CPhI North America CPhI North America

Industry Trade Show

Booth #812

20-22 May, 2025

Pennsylvania Conv Center, Philadelphia
BioProcess Internation...BioProcess International Europe

Industry Trade Show

Attending

12-15 May, 2025

Hamburg, Germany
ISPE EuropeISPE Europe

Industry Trade Show

Attending

12-14 May, 2025

London, UK

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Germany

Address

Berger Straße 8 - 10, 82319 Starnberg (Percha)

Telephone

contact-sales@aenova-group.com

Website

https://www.aenova-group.com/en

https://www.linkedin.com/company/aenova-group/

YouTube

https://www.youtube.com/@aenovaholdinggmbh6261

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Corporate Presentation

Aenova Capabilities

Gummies: A Modern Dosage Solution

Open PDF

Upload

Capsule Low-Dosing Technology to Accelerate Time-to-Market

Open PDF

Upload

Accelerating Poorly Soluble Drug Development with QbD

GMP Certificate 2025

Chewable Gels (Gummies)

Animal Health

Softgel Capsules

Development Services

Cornu Site: One-Stop Shop for all types of Soft Capsules

Feldkirchen: Center for Semi-Solids Development & Manufacturing

Interview with Aenova CEO Video Jan Kengelbach

Kirchberg Site: Center of Excellence for Pharmaceutical SGCs

Latina Sterile Area, Fill & Finish for Biologics

Muenster Site: Solids with Highly-Potent & Low-Dosed APIs

Regensburg Site: Competence Center for Solids with HPAPIs

Semi-Solids Dosage Form

Sisseln Site: Center for Complex Solids & Novel Technologies

Softgel Capsules

Solid Dosage Form

Tittmoning Site: Competence Center for Conventional Solids

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025.

Impressions: 3039

Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17 13 37 Taiwan 9 6 5 4 24 Switzerland 15 4 4 23 France 16 6 22 Japan 18 1 19 United Kingdom 12 1 2 15 Mexico 9 1 1 11 Ireland 5 5 1 11 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years.

Impressions: 13437

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 3717

NEWS #PharmaBuzz

New Managing Director at Aenova's Regensburg site

21 Mar 2025

// PRESS RELEASE

Aenova recognized as a winner of CDMO Leadership Awards 2025

07 Mar 2025

// PRESS RELEASE

Aenova invests in packaging & production at its Bad Aibling site

04 Mar 2025

// PRESS RELEASE

Lean Management at Aenova Expert Exchange for Best Practices

16 Jan 2025

// PRESS RELEASE

Aenova Donates €10,000 toBavarian Bone Marrow Donation Foundation

12 Dec 2024

// PRESS RELEASE

Sustainability award for exhibition stand of Aenova

21 Nov 2024

// PRESS RELEASE

Services

Discover the service capabilities from this company

Packaging

Discover their expertise for :

Contract Services

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drug Product Manufacturing

Discover their expertise for :

Gel

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Nasal

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Liquid

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Powder

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Solution

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Suspension

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Suppository

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Biologic Drugs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Softgel Capsule

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Injectable / Parenteral

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Capsule

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Tablet

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API & Drug Product Development

Discover their expertise for :

Formulation Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY SERVICES

TOP RANKED SUPPLIER FOR:

Contract Manufacturing of Liquid Products

Inspections and registrations

Check the inspections & registration from this company

FDA

01 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : Official Action Indicated

Inspection End Date : 2024-02-21

Aenova Group

City : Latina

State :

Country/Area : IT

Zip :

District :

Center :

Project Area : Pre-Approval Eval. of Animal Dru...

District Decision : Official Action Indicated

Inspection End Date : 2024-02-21

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : Voluntary Action Indicated

Inspection End Date : 2023-06-29

Aenova Group

City : Kirchberg SG

State :

Country/Area : CH

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2023-06-29

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : Voluntary Action Indicated

Inspection End Date : 2022-11-15

Aenova Group

City : Wolfratshausen

State :

Country/Area : DE

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2022-11-15

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : Voluntary Action Indicated

Inspection End Date : 2022-07-29

Aenova Group

City : Latina

State :

Country/Area : IT

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2022-07-29

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

05 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : No Action Indicated

Inspection End Date : 2021-11-24

Aenova Group

City : Munster

State :

Country/Area : DE

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : No Action Indicated

Inspection End Date : 2021-11-24

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

06 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : Voluntary Action Indicated

Inspection End Date : 2020-08-05

Aenova Group

City : Wolfratshausen

State :

Country/Area : DE

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2020-08-05

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

07 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : No Action Indicated

Inspection End Date : 2019-09-27

Aenova Group

City : Kirchberg SG

State :

Country/Area : CH

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : No Action Indicated

Inspection End Date : 2019-09-27

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

08 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : Voluntary Action Indicated

Inspection End Date : 2019-06-07

Aenova Group

City : Ratisbon

State :

Country/Area : DE

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2019-06-07

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

09 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : No Action Indicated

Inspection End Date : 2018-12-07

Aenova Group

City : Gronau (Leine)

State :

Country/Area : DE

Zip :

District :

Center :

Project Area : Monitoring of Marketed Animal Dr...

District Decision : No Action Indicated

Inspection End Date : 2018-12-07

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

10 FDA Audited

USA

ISPE Europe

Attending

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

District Decision : No Action Indicated

Inspection End Date : 2018-12-07

Aenova Group

City : Gronau (Leine)

State :

Country/Area : DE

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : No Action Indicated

Inspection End Date : 2018-12-07

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EDQM

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GDUFA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Company profile for Aenova Group

VISIT THE VIRTUAL BOOTH

Review portfolio & marketing content

CONTACT DETAILS

Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

DIGITAL CONTENT

22 Corporate Content #SupplierSpotlight

3 Data Compilation #PharmaFlow

57 News #PharmaBuzz

SERVICES

Packaging

Drug Product Manufacturing

API & Drug Product Development

KEY SERVICES

INSPECTIONS & REGISTRATIONS

48 FDA

8 EDQM

7 GDUFA

01

FDA Audited

02

FDA Audited

03

FDA Audited

04

FDA Audited

05

FDA Audited

06

FDA Audited

07

FDA Audited

08

FDA Audited

09

FDA Audited

10

FDA Audited

What are you looking for?